Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
PW Horby, M Campbell, N Staplin, E Spata… - 2021 - pesquisa.bvsalud.org
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of
a randomised, controlled, open-label, platform trial | PREPRINT-MEDRXIV loading Conteúdo …
a randomised, controlled, open-label, platform trial | PREPRINT-MEDRXIV loading Conteúdo …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
PW Horby, MJ Landray, RC Grp… - The Lancet (British …, 2021 - researchdiscovery.drexel.edu
Abstract General & Internal Medicine Life Sciences & Biomedicine Medicine, General &
Internal Science & Technology ESI Highly Cited Paper (Incites) Background In this study, we …
Internal Science & Technology ESI Highly Cited Paper (Incites) Background In this study, we …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
PW Horby, G Pessoa-Amorim, L Peto, CE Brightling… - medRxiv, 2021 - medrxiv.org
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
P Horby, M Campbell, N Staplin, E Spata, J Emberson… - Lancet, 2021 - ora.ox.ac.uk
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
PW Horby, G Pessoa-Amorim, L Peto, CE Brightling… - 2021 - europepmc.org
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
PW Horby, M Campbell, N Staplin, E Spata… - 2021 - pesquisa.bvsalud.org
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results
of a randomised, controlled, open-label, platform trial | PREPRINT-MEDRXIV loading 1 2 3 +A …
of a randomised, controlled, open-label, platform trial | PREPRINT-MEDRXIV loading 1 2 3 +A …